Dana-Farber Cancer Institute Breast Oncology Center

03/03/2026

Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that lacks estrogen, progesterone, and HER2 receptors. Because of this, it has fewer targeted treatment options compared with other breast cancer subtypes, making it more challenging to treat.

Dana-Farber continues to advance TNBC research through initiatives like the TNBC Registry, which collects clinical data, biospecimens, and patient-reported outcomes to help researchers better understand the disease and develop more personalized treatments.

🎥 Watch the full research update in the 2025–2026 EMBRACE MBC Virtual Forum Series recording: dana-farber.org/cancer-care/treatment/breast-oncology/programs/metastatic-breast-cancer/support-education

02/27/2026

Nadja’s message reminds us how important it is to talk with our doctors about all treatment options - including clinical trials. Clinical trials help discover new and better ways to treat breast cancer, and every conversation starts with a question.

Ask your doctor today if a clinical trial may be right for you.

02/26/2026

Assess Your Risk: Resources and Tools to Help You Take Charge of Your Health

No one wants to think about cancer. Fortunately, we are learning new ways to prevent, find, and treat cancer every day.

AssessYourRisk is a free online tool that helps you understand your personal risk for breast and ovarian cancer. In just 5–10 minutes, you will answer questions about your lifestyle, health history, family health history, and genetic testing.

The tool provides personalized recommendations and resources to help you manage or reduce your risk.

Who can use this tool?
• Adults 18+ with no personal history of breast or ovarian cancer

Learn more about your personal risk, take the quiz today: assess-your-risk.dana-farber.org

02/25/2026

La salud sexual suele pasarse por alto en el tratamiento del cáncer, pero es una parte fundamental de tu bienestar. 💜

El tratamiento del cáncer de mama puede afectar la intimidad, la salud vaginal y la fuerza del suelo pélvico de diversas maneras. Desliza para obtener más información, consultar preguntas frecuentes y recibir consejos para afrontar estos cambios.

El Programa de Salud Sexual de Dana-Farber brinda apoyo a personas y parejas de todos los géneros e identidades sexuales, ayudándoles a abordar el malestar, los síntomas de la menopausia, la imagen corporal, las preocupaciones sobre la fertilidad y mucho más.

Para obtener más información sobre el programa, visita el enlace que aparece en nuestro perfil.

02/24/2026

Patients who discuss clinical trials early with their doctor can better understand their options and make informed decisions about their care.

Every treatment journey is unique. Mary encourages you to: “Ask your doctor today if a clinical trial may be right for you.”

She’s living life fully, supported by her family and friends every step of the way.

02/23/2026

This study will look at the impact of scalp cooling in patients with metastatic breast cancer who are receiving chemotherapy.

Scalp cooling is a technique used during chemotherapy to help reduce hair loss. It works by lowering the temperature of the scalp, which may reduce the amount of chemotherapy that reaches hair follicles.

Participants will be randomized to receive either scalp cooling or no scalp cooling during their treatment. Researchers will assess how scalp cooling affects patients’ experiences and quality of life.

For more information check out dana-farber.org/clinical-trials/21-169
Or email breastresearch@dfci.harvard.edu.

02/13/2026

🔬 A new clinical trial is now enrolling participants with metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer.

This Phase 1/2 study is testing the safety and effectiveness of a new drug currently known as (Avmapki®). This drug will be given in combination with the drugs ((Verzenio®) and (Faslodex®).

Participants will receive the study drugs for as long there are no serious side effects and the disease does not get worse. The study includes a screening period, treatment period, and post-treatment follow-up, and aims to enroll about 63 participants.

For more information check out dana-farber.org/clinical-trials/22-490
Or call 877-DF-TRIAL (877-338-7425)
Or email: DFCIBreastTrials@dfci.harvard.edu

02/11/2026

📢Upcoming EMBRACE & Triage CancerWebinar on Legal and Insurance Protections Every Patient Should Know

🗓️Friday, February 13 at 1pm EST

Join us for an informational session on your rights as a cancer patient. Learn key skills, such as how to request accommodations in the workplace, apply for disability, and appeal a health insurance denial. This session will address the legal and practical issues that arise after a diagnosis and actionable next steps. A Q&A will follow the presentation.

Register today:
https://dfci.zoom.us/webinar/register/WN_F6sjK9MtRDqoh98Ohmouvg #/registration

01/05/2026

Sexual health is often overlooked in cancer care—but it’s a vital part of your well-being. 💜

Breast cancer treatment can impact intimacy, vaginal health, and pelvic floor strength in many ways. Swipe through to learn more about frequently asked questions and tips on navigating these changes.

Dana-Farber’s Sexual Health Program supports individuals and couples of all gender and sexual identities, helping address discomfort, menopausal symptoms, body image, fertility concerns, and more.

For more information about the program, please visit the link in our bio.

12/18/2025

Congratulations to Dr. Sara Tolaney on receiving the 2025 AACR Outstanding Investigator Award for Breast Cancer Research!

The award recognizes Dr. Tolaney’s groundbreaking work in optimizing targeted therapies for HER2-positive breast cancer through innovative clinical trials. Her exceptional leadership, vision, and mentorship continue to shape the field, ongoing advancements in breast cancer research and treatment.

This prestigious award was presented at the San Antonio Breast Cancer Symposium and is supported by the Breast Cancer Research Foundation and the American Association for Cancer Research.

We are proud to celebrate Dr. Tolaney’s leadership and lasting impact on the breast cancer community, and grateful for her continued dedication to improving outcomes for patients worldwide.

American Association for Cancer Research (AACR)

12/18/2025

New webinar for patients and loved ones!

Join Dr. Hal Burstein on Jan 16th to hear the latest updates on treatment and research breakthroughs for from the 2025 San Antonio Symposium .

A Q&A will follow the presentation.

Register today ⬇️⬇️
https://dfci.zoom.us/webinar/register/WN_FJYGKLwQSUmrcgRKPcJGmw #/registration

11/21/2025

Our webinar in now online! Watch Drs. Burstein, Tolaney, Lin, Lynce, and Garrido-Castro, discuss important research presented at . They discuss:
💠 for early breast cancer
💠 in advanced breast cancer
💠 in advanced breast cancer
💠 inhibitors in early breast cancer
Watch here 👉

Harold Burstein, MD, PhD; Sara Tolaney, MD, MPH; Nancy Lin, MD; Filipa Lynce, MD; and Ana C. Garrido-Castro, MD discuss important breast cancer research pres...